Skip to main content
Top
Published in: Investigational New Drugs 5/2011

01-10-2011 | PRECLINICAL STUDIES

The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity

Authors: Pere Tubert, Montserrat Rodríguez, Marc Ribó, Antoni Benito, Maria Vilanova

Published in: Investigational New Drugs | Issue 5/2011

Login to get access

Summary

We have previously described a human pancreatic-ribonuclease variant, named PE5, which carries a non-contiguous extended bipartite nuclear localization signal. This signal comprises residues from at least three regions of the protein. We postulated that the introduction of this signal in the ribonuclease provides it with cytotoxic activity because although the variant poorly evades the ribonuclease inhibitor in vitro, it is routed to the nucleus, which is devoid of the inhibitor. In this work, we have investigated the relationship between the cytotoxicity produced by PE5 and its ability to reach the nucleus. First, we show that this enzyme, when incubated with HeLa cells, specifically cleaves nuclear RNA while it leaves cytoplasmic RNA unaffected. On the other hand, we have created new variants in which the residues of the nuclear localization signal that are important for the nuclear transport have been replaced. As expected, the individual changes produce a significant decrease in the cytotoxicity of the resulting variants. We conclude that the nuclear transport of PE5 is critical for its cytotoxicity. Therefore, routing a ribonuclease to the nucleus is an alternative strategy to endow it with cytotoxic activity.
Literature
1.
go back to reference Schein CH (1997) From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Nat Biotechnol 15:529–536PubMedCrossRef Schein CH (1997) From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Nat Biotechnol 15:529–536PubMedCrossRef
2.
go back to reference Newton DL, Ryback SM (2001) Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin Biol Ther 1:995–1003PubMedCrossRef Newton DL, Ryback SM (2001) Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin Biol Ther 1:995–1003PubMedCrossRef
3.
go back to reference Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dubel S (2009) Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 9:79–95PubMedCrossRef Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dubel S (2009) Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 9:79–95PubMedCrossRef
4.
go back to reference Pavlakis N, Vogelzang NJ (2006) Ranpirnase—an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6:391–399PubMedCrossRef Pavlakis N, Vogelzang NJ (2006) Ranpirnase—an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6:391–399PubMedCrossRef
5.
go back to reference Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol Biosyst 1:294–302PubMedCrossRef Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol Biosyst 1:294–302PubMedCrossRef
6.
go back to reference De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D’Alessio G (2007) Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581:296–300PubMedCrossRef De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D’Alessio G (2007) Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581:296–300PubMedCrossRef
7.
go back to reference Leland PA, Schultz LW, Kim BM, Raines RT (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 95:10407–10412PubMedCrossRef Leland PA, Schultz LW, Kim BM, Raines RT (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 95:10407–10412PubMedCrossRef
8.
go back to reference Piccoli R et al (1999) A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. Proc Natl Acad Sci USA 96:7768–7773PubMedCrossRef Piccoli R et al (1999) A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. Proc Natl Acad Sci USA 96:7768–7773PubMedCrossRef
9.
go back to reference Vicentini AM, Kieffer B, Matthies R, Meyhack B, Hemmings BA, Stone SR, Hofsteenge J (1990) Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae. Biochemistry 29:8827–8834PubMedCrossRef Vicentini AM, Kieffer B, Matthies R, Meyhack B, Hemmings BA, Stone SR, Hofsteenge J (1990) Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae. Biochemistry 29:8827–8834PubMedCrossRef
10.
go back to reference Leland PA, Staniszewski KE, Kim BM, Raines RT (2001) Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 276:43095–43102PubMedCrossRef Leland PA, Staniszewski KE, Kim BM, Raines RT (2001) Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 276:43095–43102PubMedCrossRef
11.
go back to reference Bosch M, Benito A, Ribo M, Puig T, Beaumelle B, Vilanova M (2004) A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 43:2167–2177PubMedCrossRef Bosch M, Benito A, Ribo M, Puig T, Beaumelle B, Vilanova M (2004) A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 43:2167–2177PubMedCrossRef
12.
go back to reference Roth JS, Juster H (1972) On the absence of ribonuclease inhibitor in rat liver nuclei. Biochim Biophys Acta 287:474–476PubMed Roth JS, Juster H (1972) On the absence of ribonuclease inhibitor in rat liver nuclei. Biochim Biophys Acta 287:474–476PubMed
13.
go back to reference Rodriguez M, Benito A, Tubert P, Castro J, Ribo M, Beaumelle B, Vilanova M (2006) A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. J Mol Biol 360:548–557PubMedCrossRef Rodriguez M, Benito A, Tubert P, Castro J, Ribo M, Beaumelle B, Vilanova M (2006) A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. J Mol Biol 360:548–557PubMedCrossRef
14.
go back to reference Leland PA, Raines RT (2001) Cancer chemotherapy—ribonucleases to the rescue. Chem Biol 8:405–413PubMedCrossRef Leland PA, Raines RT (2001) Cancer chemotherapy—ribonucleases to the rescue. Chem Biol 8:405–413PubMedCrossRef
15.
go back to reference Boulanger C, Di Giorgio C, Vierling P (2005) Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40:1295–1306PubMedCrossRef Boulanger C, Di Giorgio C, Vierling P (2005) Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40:1295–1306PubMedCrossRef
16.
go back to reference Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R (2005) Cell uptake and radiotoxicity studies of an nuclear localization signal peptide-intercalator conjugate labeled with [99mTc(CO)3]+. Bioconjug Chem 16:582–587PubMedCrossRef Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R (2005) Cell uptake and radiotoxicity studies of an nuclear localization signal peptide-intercalator conjugate labeled with [99mTc(CO)3]+. Bioconjug Chem 16:582–587PubMedCrossRef
17.
go back to reference Chen P et al (2006) Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 47:827–836PubMed Chen P et al (2006) Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 47:827–836PubMed
18.
go back to reference Leland PA, Staniszewski KE, Kim B, Raines RT (2000) A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 477:203–207PubMedCrossRef Leland PA, Staniszewski KE, Kim B, Raines RT (2000) A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 477:203–207PubMedCrossRef
19.
go back to reference Canals A, Ribo M, Benito A, Bosch M, Mombelli E, Vilanova M (1999) Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability. Protein Expr Purif 17:169–181PubMedCrossRef Canals A, Ribo M, Benito A, Bosch M, Mombelli E, Vilanova M (1999) Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability. Protein Expr Purif 17:169–181PubMedCrossRef
20.
go back to reference Ribo M, Benito A, Canals A, Nogues MV, Cuchillo CM, Vilanova M (2001) Purification of engineered human pancreatic ribonuclease. Methods Enzymol 341:221–234PubMedCrossRef Ribo M, Benito A, Canals A, Nogues MV, Cuchillo CM, Vilanova M (2001) Purification of engineered human pancreatic ribonuclease. Methods Enzymol 341:221–234PubMedCrossRef
21.
22.
go back to reference Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4:2411–2423PubMedCrossRef Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4:2411–2423PubMedCrossRef
23.
go back to reference Font J, Benito A, Torrent J, Lange R, Ribo M, Vilanova M (2006) Pressure- and temperature-induced unfolding studies: thermodynamics of core hydrophobicity and packing of ribonuclease A. Biol Chem 387:285–296PubMedCrossRef Font J, Benito A, Torrent J, Lange R, Ribo M, Vilanova M (2006) Pressure- and temperature-induced unfolding studies: thermodynamics of core hydrophobicity and packing of ribonuclease A. Biol Chem 387:285–296PubMedCrossRef
24.
go back to reference Boix E, Nogues MV, Schein CH, Benner SA, Cuchillo CM (1994) Reverse transphosphorylation by ribonuclease A needs an intact p2-binding site. Point mutations at Lys-7 and Arg-10 alter the catalytic properties of the enzyme. J Biol Chem 269:2529–2534PubMed Boix E, Nogues MV, Schein CH, Benner SA, Cuchillo CM (1994) Reverse transphosphorylation by ribonuclease A needs an intact p2-binding site. Point mutations at Lys-7 and Arg-10 alter the catalytic properties of the enzyme. J Biol Chem 269:2529–2534PubMed
25.
go back to reference Leatherbarrow RJ, Fersht AR (1987) Investigation of transition-state stabilization by residues histidine-45 and threonine-40 in the tyrosyl-tRNA synthetase. Biochemistry 26:8524–8528PubMedCrossRef Leatherbarrow RJ, Fersht AR (1987) Investigation of transition-state stabilization by residues histidine-45 and threonine-40 in the tyrosyl-tRNA synthetase. Biochemistry 26:8524–8528PubMedCrossRef
26.
go back to reference Mastronicola MR, Piccoli R, D’Alessio G (1995) Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease. Eur J Biochem 230:242–249PubMedCrossRef Mastronicola MR, Piccoli R, D’Alessio G (1995) Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease. Eur J Biochem 230:242–249PubMedCrossRef
27.
go back to reference Liao YD, Huang HC, Chan HJ, Kuo SJ (1996) Large-scale preparation of a ribonuclease from Rana catesbeiana (bullfrog) oocytes and characterization of its specific cytotoxic activity against tumor cells. Protein Expr Purif 7:194–202PubMedCrossRef Liao YD, Huang HC, Chan HJ, Kuo SJ (1996) Large-scale preparation of a ribonuclease from Rana catesbeiana (bullfrog) oocytes and characterization of its specific cytotoxic activity against tumor cells. Protein Expr Purif 7:194–202PubMedCrossRef
28.
go back to reference Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE (2000) Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60:1983–1994PubMed Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE (2000) Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60:1983–1994PubMed
29.
go back to reference Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ (2002) Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 277:15142–15146PubMedCrossRef Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ (2002) Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 277:15142–15146PubMedCrossRef
30.
go back to reference Ardelt B, Ardelt W, Darzynkiewicz Z (2003) Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2:22–24PubMedCrossRef Ardelt B, Ardelt W, Darzynkiewicz Z (2003) Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2:22–24PubMedCrossRef
31.
go back to reference Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z (2008) The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 7:3258–3261PubMedCrossRef Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z (2008) The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 7:3258–3261PubMedCrossRef
32.
go back to reference Mondino A, Jenkins MK (1995) Accumulation of sequence-specific RNA-binding proteins in the cytosol of activated T cells undergoing RNA degradation and apoptosis. J Biol Chem 270:26593–26601PubMedCrossRef Mondino A, Jenkins MK (1995) Accumulation of sequence-specific RNA-binding proteins in the cytosol of activated T cells undergoing RNA degradation and apoptosis. J Biol Chem 270:26593–26601PubMedCrossRef
33.
go back to reference Narayanan A, Lukowiak A, Jady BE, Dragon F, Kiss T, Terns RM, Terns MP (1999) Nucleolar localization signals of box H/ACA small nucleolar RNAs. EMBO J 18:5120–5130PubMedCrossRef Narayanan A, Lukowiak A, Jady BE, Dragon F, Kiss T, Terns RM, Terns MP (1999) Nucleolar localization signals of box H/ACA small nucleolar RNAs. EMBO J 18:5120–5130PubMedCrossRef
34.
go back to reference Lukowiak AA, Narayanan A, Li ZH, Terns RM, Terns MP (2001) The snoRNA domain of vertebrate telomerase RNA functions to localize the RNA within the nucleus. RNA 7:1833–1844PubMed Lukowiak AA, Narayanan A, Li ZH, Terns RM, Terns MP (2001) The snoRNA domain of vertebrate telomerase RNA functions to localize the RNA within the nucleus. RNA 7:1833–1844PubMed
35.
go back to reference Ardelt W, Shogen K, Darzynkiewicz Z (2008) Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 9:215–225PubMedCrossRef Ardelt W, Shogen K, Darzynkiewicz Z (2008) Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 9:215–225PubMedCrossRef
36.
go back to reference Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H (2001) Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 40:7518–7524PubMedCrossRef Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H (2001) Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 40:7518–7524PubMedCrossRef
37.
go back to reference Makarov AA, Ilinskaya ON (2003) Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 540:15–20PubMedCrossRef Makarov AA, Ilinskaya ON (2003) Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 540:15–20PubMedCrossRef
38.
go back to reference Costanzi J, Sidransky D, Navon A, Goldsweig H (2005) Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 23:643–650PubMedCrossRef Costanzi J, Sidransky D, Navon A, Goldsweig H (2005) Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 23:643–650PubMedCrossRef
Metadata
Title
The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity
Authors
Pere Tubert
Montserrat Rodríguez
Marc Ribó
Antoni Benito
Maria Vilanova
Publication date
01-10-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9426-2

Other articles of this Issue 5/2011

Investigational New Drugs 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine